Clinical Research Directory

Inclusion Criteria: * Diagnosis of primary and recurrent glioma; * Sequential injection of 99mTc-1-thio-D-glucose and 18F-FET in the interval of 14 days in each patient; * Hematological, liver and renal function test results within the following limits: * White blood cell count: \> 2.0 x 109/L * Hemoglobin: \> 80 g/L * Platelets: \> 50.0 x 109/L * Alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST): =\< 5.0 times Upper Limit of Normal * Bilirubin =\< 2.0 times Upper Limit of Normal * Serum creatinine: Within Normal Limits * A negative pregnancy test for all patients of childbearing potential. Sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception for at least 30 days after study termination; * Subject is capable to undergo the diagnostic investigations to be performed in the study; * Informed consent. Exclusion Criteria: * Second, non-brain malignancy; * Active current autoimmune disease or history of autoimmune disease; * Active infection or history of severe infection within the previous 3 months (if clinically relevant at screening); * Known HIV positive or chronically active hepatitis B or C; * Administration of other investigational medicinal product within 30 days of screening; * Ongoing toxicity \> grade 2 from previous standard or investigational therapies, according to US National Cancer Institute's.